"Nadolol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.
Descriptor ID |
D009248
|
MeSH Number(s) |
D02.033.100.624.698.601 D02.033.755.624.698.601 D02.092.063.624.698.601
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nadolol".
Below are MeSH descriptors whose meaning is more specific than "Nadolol".
This graph shows the total number of publications written about "Nadolol" by people in this website by year, and whether "Nadolol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2020 | 1 | 1 | 2 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nadolol" by people in Profiles.
-
The effects of normoxic endurance exercise on erythropoietin (EPO) production and the impact of selective ?1 and non-selective ?1?+??2 adrenergic receptor blockade. Eur J Appl Physiol. 2021 May; 121(5):1499-1511.
-
Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats. Neurosci Lett. 2020 04 23; 725:134892.
-
Systemic ?-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of V?9Vd2 T-Cells. Front Immunol. 2019; 10:3082.
-
?2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav Immun. 2018 11; 74:143-153.
-
Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the ?2-adrenergic receptor. Brain Behav Immun. 2018 02; 68:66-75.